

PRESSURE BIOSCIENCES INC.

14 Norfolk Avenue
South Easton, MA 02375
(T) 508-230-1828
(F) 508-230-1829
info@pressurebiosciences.com

Mr. Richard T. Schumacher, CEO, President
Dr. Edmund Y. Ting, SVP of Engineering
Dr. Nathan P. Lawrence, Vice President of M&S
Dr. Alexander V. Lazarev, Vice President of R&D
Mr. Joseph L. Damasio Jr, VP of Finance and CFO

STOCK OVERVIEW

Symbol:	PBIO	Recent Close:	\$3.70 (as of 07/08/18)
Exchange:	OTCQB	52-Week Range:	\$0.70 - \$7.90
Shares OS ¹ :	1.4M (7.1M FD)	Market Capitalization ² :	\$5.5M (28M FD)
Float:	~1.0M	Fiscal Year End:	December 31
Revenue (FY2017):	\$2.24M	Transfer Agent:	Computershare

COMPANY OVERVIEW

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. Our products/services are based on three patented, pressure-enhanced platforms: (i) Pressure Cycling Technology (“PCT”), (ii) Pressure Enabled Protein Manufacturing Technology (“PreEMT”), and (iii) Ultra Shear Technology (“UST”).

The PCT Platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). Our primary focus is in making our recently-released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization and quality control of biotherapeutic drugs. The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in approximately 175 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders. The PCT Platform is offered through the Company’s Research Products & Services Group.

The PreEMT Platform can be used to significantly impact and improve the quality of protein therapeutics. It employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. The PreEMT Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. The PreEMT Platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. It is scaleable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations. Research and manufacturing licenses are available.

The UST Platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.

1. Shares Outstanding (as of June 18, 2018) – includes approximately 1.4M common shares and 5.7M common share equivalents from Preferred Stock Series D, G, H, J, K, and AA on an as-converted basis.
2. Fully Diluted Market Capitalization is calculated using Common Stock OS and Common Equivalent Shares OS on a Fully Diluted basis.

INVESTMENT HIGHLIGHTS

- Seasoned Management Team & Board of Directors
- Novel, Enabling, Patent Protected, Proprietary Pressure-based Platforms
- Proven Core Technology with Multiple Applications (Over 300 PCT Systems Installed)
- Razor/Razorblade Business Model
- Sales into the Research Market (fast market penetration with minimal approvals required)
- Increasing Number of 3rd Party Publications from Marquee Laboratories
- PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery
- PreEMT Can Impact and Improve Protein Drug Therapeutics
- UST Offers the Potential to Produce Highly Stable Nanoemulsions, Including in the Food and CBD Markets
- Significant Market Opportunity (~\$6 Billion from ~500K Scientists in 80K Labs Worldwide)

RECENT & KEY ANNOUNCEMENTS

- **June 12, 2018:** the Company announced the conversion an additional \$7.24M of Debt into Equity, making a total of \$13.6M of debt that the Company had converted into equity from mid-May to mid-June 2018.
- **May 15:** the Company announced the conversion of \$6.39M of debt into equity.
- **May 15:** the Company reported continued revenue increases for Q1 2018, including an 11% increase in products and services sales, an 8% increase in instrument sales, and an 18% increase in consumable sales YoY.
- **May 3:** the Company announced receipt of the first contract utilizing the recently acquired high pressure technology from BaroFold, Inc. to evaluate PBI's patented Pre-EMT platform to enhance the manufacturing process and improve the quality of protein therapeutic drug candidates.
- **April 3:** the Company reported Q4 and FY2017 financial results. Instruments, consumables, products & services and total revenue continued to show double-digit growth. Quarterly revenue has increased eight quarters in a row, on a Y/Y basis. Total revenue has increased four years in a row, on a Y/Y basis.
- **February 14:** the Company announced a two-year, worldwide co-marketing and distribution agreement with ISS, Inc., a global supplier of high pressure optical cell systems. The companies plan to replace the current manual pressure generator for the ISS optical cell with PBI's computer-controlled, automated instruments.
- **December 20, 2017:** the Company announced a significant software upgrade for its flagship Barocycler 2320EXTREME instrument.
- **December 18:** the Company announced it would host an investor call to discuss the BaroFold asset purchase, the recently patented Ultra Shear Technology ("UST") platform, enhancements to its core pressure-based instrument and consumables business, and would offer a brief outlook for FY2018.
- **December 13:** the Company announced the acquisition of all the assets of BaroFold Corp, and its immediate entry into the Biologics Contract Research Services Sector.
- **November 14:** the Company reported third quarter 2017 financial results, including record total revenue led by increases in products and services (+21%), consumables (+158%), and grant (+23%) sales.
- **November 1:** the Company announced the initiation of an aggressive marketing and sales strategy that PBI expects will drive significant expansion in China.
- **October 18:** the Company announced a strategic collaboration with Phasex Corporation, to combine PBI's Ultra Shear Technology with Phasex's Supercritical Fluid Processing Method to enable the development of stable, water-soluble nanoemulsions, including CBD-enriched plant oil.
- **October 10:** the Company announced multiple presentations at scientific meetings in Germany, Poland, and Ireland highlighting the features & benefits of the Company's next-generation Barocycler 2320EXT instrument.
- **October 2:** the Company announced it was issued two patents on its widely-applicable, high pressure-based Ultra Shear Technology. PBI believes that UST can be used to create or improve a broad range of medical, consumer, and industrial products through the preparation of high quality nanoemulsions and "clean label" food.
- **September 18:** the Company announced that the Barocycler 2320EXTREME was named a Finalist in the prestigious 2017 R&D 100 Awards. Considered among the most prestigious recognitions of invention and innovation worldwide, the R&D 100 awards identify the top 100 revolutionary technologies of the past year.
- **June 6:** the Company announced that the Barocycler 2320EXTREME was to be featured in multiple presentations all week at the major ASMS scientific conference, and that compelling advantages of the Company's PCT platform were highlighted in two different mass spectrometry user meetings on Day One.
- **June 5:** the Company announced that Dr. Ruedi Aebersold received the prestigious Karger Medal for significant contributions to the development of new bioanalytical methods, and that he discussed PBI's patented PCT platform for sample preparation – a critical step in scientific analysis – during his Medal Lecture
- **March 1:** the Company's Barocycler, the 2320EXTREME, received the 2017 N. American Excellence Award for "Best New Instrument for Sample Preparation" by Corporate America News, a leading business publication.

BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

07/08/2018